Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.46 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.46 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | RARB | P10826 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24473432 | 0.84 | PTGS1 (0.47) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL7784324 | 0.83 | PTGS1 (0.43) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL547420 | 0.82 | TSHR (0.62) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL8567450 | 0.82 | PTGS1 (0.42) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL28905884 | 0.82 | PTGS1 (0.42) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL4859307 | 0.82 | ESR1 (0.60) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL8568757 | 0.82 | PTGS1 (0.42) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL8568763 | 0.82 | PTGS1 (0.42) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL7323204 | 0.79 | PTGS1 (0.51) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL11766801 | 0.79 | PTGS1 (0.47) | PTGS1PTGS2LMNACYP2C9AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227499-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-07-20 | — | — | US | disclosed |
| US-10696857-B2 | Curable gellant ink | XEROX CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190185694-A1 | Curable Gellant Ink | XEROX CORPORATION | 2019-06-20 | — | — | US | disclosed |
| US-10308827-B2 | Ink jet ink compositions for digital manufacturing of transparent objects | XEROX CORPORATION (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180105712-A1 | Ink Composition Comprising Phase Change Transfer Additive For Digital Offset Printing | XEROX CORPORATION | 2018-04-19 | — | — | US | disclosed |
| US-20180105712-A1 | Ink Composition Comprising Phase Change Transfer Additive For Digital Offset Printing | XEROX CORPORATION | 2018-04-19 | — | — | US | disclosed |
| US-9884048-B2 | ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170275486-A1 | Curable Gellant Ink Composition | XEROX CORPORATION | 2017-09-28 | — | — | US | disclosed |
| US-20170275486-A1 | Curable Gellant Ink Composition | XEROX CORPORATION | 2017-09-28 | — | — | US | disclosed |
| US-20170266167-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007062314-A2 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062342-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| EP-0668259-A1 | A method for the preparation of optically active 2-aryl alkyl aldehydes and formation of 2-aryl-alkanoic acids therefrom | MEDICEChem.-Pharm. Fabrik Pütter GmbH & Co. KG (DE) | 1995-08-23 | — | — | EP | disclosed |
| US-5434302-A | Method for the preparation of optically active 2-aryl alkyl aldehydes and formation of 2-aryl-alkanoic acids therefrom | PARADIES H HENRICH (DE) | 1995-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | PTGS1 2769/4885PTGS2 3794/4885LMNA 170/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | PTGS1 2769/4885PTGS2 3794/4885LMNA 170/4885 |
| US-20170266167-A1 | ERK INHIBITORS | MAPK1, MAPK3, MAPK6 | PTGS1 1174/4885PTGS2 1785/4885LMNA 4756/4885 |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | PTGS1 2769/4885PTGS2 3794/4885LMNA 170/4885 |
| US-20230227499-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | PITRM1, NME4, PDF | PTGS1 1415/4885PTGS2 1422/4885LMNA 2603/4885 |
| US-10696857-B2 | Curable gellant ink | LCP1, CCNT1, CRBN | PTGS1 1742/4885PTGS2 2396/4885LMNA 1692/4885 |
| US-20190185694-A1 | Curable Gellant Ink | LCP1, CCNT1, CRBN | PTGS1 1742/4885PTGS2 2396/4885LMNA 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.